IL-3

General Information


DRACP ID  DRACP00642

Peptide Name   IL-3

Sequence  FKIGGFIKKAWRSLLA

Sequence Length  16

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma IC50=93.5±19.4 μM MTT assay 2h 1
PC-3 Prostate carcinoma Carcinoma IC50=74.9±13.3 μM MTT assay 2h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  HEK293T: IC50=48.5±4.9 μM; WPMY-1: IC50=40.1±6.9 μM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00642

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C90H143N23O18

Absent amino acids  CDEHMNPQTVY

Common amino acids  K

Mass  210301

Pl  11.92

Basic residues  4

Acidic residues  0

Hydrophobic residues  9

Net charge  4

Boman Index  -150

Hydrophobicity  44.38

Aliphatic Index  110

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  5500

Absorbance 280nm  366.67

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 27778166

Title  Isoleucine/leucine residues at "a" and "d" positions of a heptad repeat sequence are crucial for the cytolytic activity of a short anticancer lytic peptide

Doi 10.1007/s00726-016-2350-9

Year  2017

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.